ACM
AKTX

Accent Capital Management’s Akari Therapeutics AKTX Stock Holding History

Accent Capital Management’s Portfolio AKTX Stock Details AKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-125
Closed -$1.45K – 336
2025
Q4 		$1.45K Sell
125
-125
-50% -$2.9K ﹤0.01% 344
2025
Q3 		$10.1K Hold
250
– – ﹤0.01% 205
2025
Q2 		$11.7K Hold
250
– – 0.01% 212
2025
Q1 		$12.4K Hold
250
– – 0.01% 185
2024
Q4 		$12.2K Buy
+250
New +$18.8K 0.01% 137

Other funds holding AKTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TC
Truvestments Capital Sarasota, Florida $554M AUM 32.49% 1-Year Est. Return

Accent Capital Management's AKTX Position: Q1 2026 in Review

Accent Capital Management sold out of Akari Therapeutics (AKTX) in Q1 2026, closing a stake of 125 shares — an estimated $1.45K sold.

Accent Capital Management first reported a position in AKTX in Q4 2024 and held it in 5 quarters. The position peaked at $12.4K in Q1 2025. 6 funds tracked by Wall St. Rank hold AKTX as of Q1 2026.

  • Accent Capital Management reported no remaining Akari Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Accent Capital Management sold 125 Akari Therapeutics shares in Q1 2026, an estimated $1.45K.
  • Accent Capital Management first reported a position in Akari Therapeutics in Q4 2024 and held it in 5 quarters.
  • Accent Capital Management's Akari Therapeutics position peaked at $12.4K in Q1 2025.
  • 6 funds tracked by Wall St. Rank held Akari Therapeutics as of Q1 2026.

Based on Accent Capital Management's 13F filing for Q1 2026, filed 11 May 2026.